NCT06544642View on ClinicalTrials.gov

A Study to Evaluate the Effects of ASP5502 in Healthy Adults and Adults With Primary Sjögren's Syndrome

PHASE1RecruitingINTERVENTIONAL

Enrollment

132

Participants

Timeline

Start Date

August 21, 2024

Primary Completion Date

July 31, 2027

Study Completion Date

July 31, 2027

Conditions

Healthy VolunteersSjögren's Syndrome

Interventions

DRUG

ASP5502

Oral

DRUG

Placebo

Oral

Trial Locations (1)

32117

RECRUITING

Fortrea Clinical Research Unit Inc, Daytona Beach

All Listed Sponsors

lead

Astellas Pharma Global Development, Inc.

INDUSTRY